Collegium Pharmaceutical, Inc. (COLL) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Ligand Pharmaceuticals, Inc.

Innoviva, Inc.

Collegium Pharmaceutical, Inc.

ImmunityBio, Inc.

Ardelyx, Inc.

Revance Therapeutics, Inc.

Day One Biopharmaceuticals, Inc.

Keros Therapeutics, Inc.

Morphic Holding, Inc.

ACELYRIN, Inc.

EQRx, Inc.

Why is Collegium Pharmaceutical, Inc. ?

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.55
The company has been able to generate a Return on Capital Employed (avg) of 18.24% signifying low profitability per unit of total capital (equity and debt)

Healthy long term growth as Net Sales has grown by an annual rate of 20.28% and Operating profit at 26.76%

The company has declared Positive results for the last 3 consecutive quarters

NET PROFIT(HY) At USD 41.85 MM has Grown at 138.69%
OPERATING CASH FLOW(Y) Highest at USD 331.04 MM
RAW MATERIAL COST(Y) Fallen by -10.87% (YoY)

With ROCE of 22.24%, it has a attractive valuation with a 1.91 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 14.40%, its profits have fallen by -15.8%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Collegium Pharmaceutical, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Collegium Pharmaceutical, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Collegium Pharmaceutical, Inc.

14.4%

0.03

40.27%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

20.28%

EBIT Growth (5y)

26.76%

EBIT to Interest (avg)

1.55

Debt to EBITDA (avg)

3.22

Net Debt to Equity (avg)

3.17

Sales to Capital Employed (avg)

0.61

Tax Ratio

32.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

18.24%

ROE (avg)

24.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.51

EV to EBIT

8.61

EV to EBITDA

3.86

EV to Capital Employed

1.91

EV to Sales

2.03

PEG Ratio

Dividend Yield

ROCE (Latest)

22.24%

ROE (Latest)

25.00%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET PROFIT(HY)

At USD 41.85 MM has Grown at 138.69%

OPERATING CASH FLOW(Y)

Highest at USD 331.04 MM

RAW MATERIAL COST(Y)

Fallen by -10.87% (YoY

CASH AND EQV(HY)

Highest at USD 848.13 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 3.48 times

-2What is not working for the Company

PRE-TAX PROFIT(Q)

At USD 19.81 MM has Fallen at -29.88%

Here's what is working for Collegium Pharmaceutical, Inc.

Net Profit

At USD 41.85 MM has Grown at 138.69%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow

Highest at USD 331.04 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Cash and Eqv

Highest at USD 848.13 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 3.48 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -10.87% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Collegium Pharmaceutical, Inc.

Pre-Tax Profit

At USD 19.81 MM has Fallen at -29.88%

over average net sales of the previous four periods of USD 28.25 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)